肺部立体定向放疗后的生活质量:II期STRIPE试验结果
前瞻性单中心II期STRIPE试验纳入100例≤2个≤5cm肺部病灶患者,行4DPET/CT引导SBRT(3×12.5Gy或风险适应5×7Gy),评估长期生活质量、疗效与毒性。结果显示总体生活质量稳定,初始QoL/GHS低者改善更显著,2年局部进展概率8.1%,≥G3毒性<4%,但≥G3呼吸困难从基线6%升至2年14.5%。
要点
- SBRT后长期总体生活质量、功能评分和症状保持稳定。
- 初始QoL/GHS低于中位数的患者改善显著更强(p<0.001)。
- 2年局部进展概率8.1%,≥G3毒性<4%,但≥G3呼吸困难2年达14.5%。
核心结论
- 代表性肺部SBRT患者的前瞻性数据证实SBRT后健康相关生活质量稳定保留。
- 初始QoL/GHS评分低的患者从SBRT中获得QoL/GHS获益。
- 3×12.5Gy SBRT方案有效且耐受良好,可为 frail 患者共享决策提供信息。
研究设计与样本
- 前瞻性单中心II期STRIPE试验,2011年2月至2014年11月纳入100例患者。
- 患者肺部病灶≤2个、≤5cm,接受4DPET/CT引导SBRT(3×12.5Gy或风险适应5×7Gy,至60%等剂量线)。
- 随访为SBRT后2周、7周,然后每3个月至2年,评估疗效、毒性和HRQOL(EORTC QLQ-C30和EORTC QLQ-LC13)。
主要发现
- 100例中56例NSCLC、44例肺转移(M1);长期随访总体QoL/GHS、功能评分和症状稳定。
- 初始QoL/GHS低于中位数者改善显著强于初始评分良好者(p<0.001)。
- SBRT后2年局部进展概率8.1%(NSCLC 7.3%,M1 9.2%),局部无进展生存53.3%(NSCLC 50.7%,M1 56.0%),总生存62.2%(NSCLC 57.2%,M1 68.4%)。
- ≥G3毒性<4%,但≥G3呼吸困难基线为6%,SBRT后2年为14.5%。
关键数值与推荐
- SBRT剂量方案:3×12.5Gy或风险适应5×7Gy,处方至60%等剂量线。
- 主要终点为2年局部进展累积发生率,次要终点包括LPFS、OS和毒性(CTCAE)。
- HRQOL评估采用EORTC QLQ-C30和EORTC QLQ-LC13。
临床怎么用
- 对肺部寡病灶患者,SBRT可维持长期生活质量,尤其初始QoL/GHS低者可能获益更明显。
- 3×12.5Gy方案有效且耐受良好,可用于 frail 患者的共享决策讨论。
- 需关注SBRT后≥G3呼吸困难风险(2年14.5%),基线6%。
局限性
- 单中心II期试验,样本量100例,结论需更大样本验证。
- 原文未报告随机对照或盲法设计。
- 原文未报告长期随访的具体中位时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Preserving health related quality of life (HRQOL) plays an important role in considering stereotactic body fractionated radiotherapy (SBRT). The prospective monocenter phase II STRIPE trial investigated long-term HRQOL after SBRT, efficacy and toxicity. MATERIALS AND METHODS: Patients with ≤2 pulmonary lesions ≤5 cm were treated with 4DPET/CT-based SBRT (3 × 12.5 Gy or risk-adapted 5 × 7 Gy, to 60% isodose). Follow up (FU) was performed 2 and 7 weeks after SBRT, then 3-monthly for 2 years with assessment of response (primary endpoint: 2-year cumulative incidence of local progression (LP); secondary endpoints: local progression free survival (LPFS), overall survival (OS) and toxicity (CTCAE)). Impact of predefined patient and treatment related factors on HRQOL (EORTC QLQ-C30 and EORTC QLQ-LC13) was evaluated. RESULTS: Between 02/2011 and 11/2014, 100 patients were given SBRT for 56 NSCLC and 44 pulmonary metastases (M1). Long-term FU overall revealed stable Quality of Life (QoL)/Global health status (GHS), functions-scores and symptoms. For QoL/GHS, patients with low (<median) initial QoL/GHS-Score revealed significantly stronger improvement than those with good QoL/GHS-scores (p < 0.001). Probability for LP, LPFS and OS 2 years after SBRT was 8.1% (NSCLC: 7.3%, M1:9.2%), 53.3% (NSCLC: 50.7%, M1: 56.0%) and 62.2% (NSCLC: 57.2%, M1: 68.4%). ≥G3-Toxicity was <4%, but ≥G3 dyspnea was 6% at baseline and 14.5% 2 years after SBRT. CONCLUSIONS: These prospective data on representative pulmonary SBRT patients confirm stable preservation of HRQOL after SBRT and demonstrate a QoL/GHS-benefit for patients with low initial QoL/GHS-scores, the regimen of 3 × 12.5 Gy SBRT being efficient and well tolerated. This result may inform shared decision making when discussing SBRT for frail patients.
引用
- Nestle U, Adebahr S, Kaier K, et al. Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiother Oncol. 2020. PMID: 32339780. doi:10.1016/j.radonc.2020.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。